<code id='D2F099EF84'></code><style id='D2F099EF84'></style>
    • <acronym id='D2F099EF84'></acronym>
      <center id='D2F099EF84'><center id='D2F099EF84'><tfoot id='D2F099EF84'></tfoot></center><abbr id='D2F099EF84'><dir id='D2F099EF84'><tfoot id='D2F099EF84'></tfoot><noframes id='D2F099EF84'>

    • <optgroup id='D2F099EF84'><strike id='D2F099EF84'><sup id='D2F099EF84'></sup></strike><code id='D2F099EF84'></code></optgroup>
        1. <b id='D2F099EF84'><label id='D2F099EF84'><select id='D2F099EF84'><dt id='D2F099EF84'><span id='D2F099EF84'></span></dt></select></label></b><u id='D2F099EF84'></u>
          <i id='D2F099EF84'><strike id='D2F099EF84'><tt id='D2F099EF84'><pre id='D2F099EF84'></pre></tt></strike></i>

          focus

          focus

          author:knowledge    Page View:8957
          Several amyloid plaques forming between neurons in a brain
          Adobe

          Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

          The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

          advertisement

          “I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          Sutter Health’s antitrust win overturned by appeals court
          Sutter Health’s antitrust win overturned by appeals court

          AdobeWhenSutterHealthwasontrialforanticompetitiveconductin2022,theSanFranciscojurymissedoutonsomecru

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Data don't support strong claims for Covid

          ChristopherFurlong/GettyImagesInthemidstoftheCovid-19pandemic,scientistsandpublichealthinstitutionsm